<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">abd</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27828646</article-id>
      <article-id pub-id-type="pmc">5087231</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20164316</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Primary localized cutaneous amyloidosis with lichen and
poikiloderma-like lesions and an excellent response to systemic acitretin<xref ref-type="fn" rid="fn1">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>MA</surname>
            <given-names>Han</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Su</surname>
            <given-names>Xiangyang</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhu</surname>
            <given-names>Guoxing</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yin</surname>
            <given-names>Songchao</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>Chun</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lai</surname>
            <given-names>Wei</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Third Affiliated Hospital, Sun Yat-sen University &#x2013;
Guangdong, China</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1">Mailing address: Xiangyang Su, Department of Dermatology the Third
Affiliated Hospital, Sun Yat-sen University, 600 Tianhe Road Guangzhou,
Guangdong, 510630, China. E-mail: <email>sh3355@vip.163.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Sep-Oct</season>
        <year>2016</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2016</year>
      </pub-date>
      <volume>91</volume>
      <issue>5</issue>
      <fpage>661</fpage>
      <lpage>663</lpage>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>12</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>1</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2016 by Anais Brasileiros de
Dermatologia</copyright-statement>
        <copyright-year>2016</copyright-year>
        <copyright-holder>Anais Brasileiros de Dermatologia</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Primary localized cutaneous amyloidosis is a skin-limited amyloidosis that does
not involve internal organs. It is clinically subclassified into 3 general
categories and some rare variants. However, there is considerable overlap within
the classification. Though there are a variety of therapeutic measures, the
treatment is often unsatisfactory, particularly when the disease is severe and
extensive. We describe a rare case of primary localized cutaneous amyloidosis
with lichen and poikiloderma-like lesions that showed an excellent response to
systemic acitretin.</p>
      </abstract>
      <kwd-group>
        <kwd>Acitretin</kwd>
        <kwd>Amyloidosis</kwd>
        <kwd>Lichens</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Primary localized cutaneous amyloidosis (PLCA) is characterized by the limited
deposition of amyloid in the skin, without deposition in any internal
organs.<sup><xref rid="r1" ref-type="bibr">1</xref></sup> There are a
variety of clinical phenotypes and treatment is often difficult, particularly when
the disease is severe and extensive. In this study, we describe a rare case of PLCA
with lichen and poikiloderma-like lesions and an excellent response to systemic
acitretin.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 22-year-old woman had endured multiple, mildly pruritic, red-purple skin lesions on
her face, external ear, neck and upper back for twenty years (<xref ref-type="fig" rid="f1">Figure 1</xref>).<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r3" ref-type="bibr">3</xref></sup> The eruptions initially developed as
papules on her face and spread gradually to the other locations. Some lesions on the
forehead and bilateral parts of the malar region and cheeks (is this a repetition of
the same idea?) coalesced into plaques, while others on the upper back partly
subsided spontaneously, leaving hypopigmented macules. Her medical history was
unremarkable and there were no reports of a similar condition in her family members.
Physical examination revealed symmetric, multiple, red-purple, hyperkeratotic
papules and plaques on the face, external ear and neck. The papules were
intermingled with hypopigmented macules and telangiectatica, producing a reticulated
appearance on the upper back. Laboratory examination showed no abnormality in
routine tests, including blood count, urinalysis, liver and kidney function test,
muscle enzymes and serum uric acid level. Serum and urine immunofixation returned
negative results. No cardiac abnormalities were noted upon echocardiography. A skin
biopsy specimen revealed hyperkeratosis, focal hypergranulosis, irregular
acanthosis, liquefaction degeneration of the basal layer, and aggregations of
amorphous eosinophilic material and pigment incontinence in the papillary dermis
(<xref ref-type="fig" rid="f2">Figure 2A</xref>). The eosinophilic material
stained positively with Congo red (<xref ref-type="fig" rid="f2">Figure 2B</xref>).
Based on the clinical manifestations and histopathological features, the patient was
diagnosed with PLCA and treated with systemic acitretin at an initial dose of 0.5
mg/kg/d (30 mg/d). The patient experienced clear relief from pruritus and saw some
improvement in the papules and plaques 6 months later, with mild mucocutaneous side
effects (<xref ref-type="fig" rid="f1">Figure 1</xref>).<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r3" ref-type="bibr">3</xref></sup> Furthermore,
18 months later, (later was missing but presumably that is what was meant?) the case
showed a remarkably good response to the medicine (<xref ref-type="fig" rid="f1">Figure 1</xref>).<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r3" ref-type="bibr">3</xref></sup></p>
      <p>
        <fig id="f1" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Skin lesions on the face (A1, A2) and upper back (A3). 6 months (B1-3)
and 18 months (C1-3) after treatment with systemic acitretin</p>
          </caption>
          <graphic xlink:href="abd-91-05-0661-g01"/>
        </fig>
      </p>
      <p>
        <fig id="f2" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <p>The histological findings. (A) Hyperkeratosis, liquefaction degeneration
of the basal layer, aggregations of amorphous eosinophilic material and
pigment incontinence in the papillary dermis (H &amp; E, 100&#xD7;).
(B) The eosinophilic material stained positively (Congo red A stain,
400&#xD7;)</p>
          </caption>
          <graphic xlink:href="abd-91-05-0661-g02"/>
        </fig>
      </p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Amyloidosis refers to a heterogeneous group of disorders characterized by
extracellular deposition of proteinaceous fibrillar materials (termed amyloid) in
various tissues and organs.<sup><xref rid="r2" ref-type="bibr">2</xref></sup> At
present, there are 30 structurally unrelated proteins that are known to cause
amyloidosis.<sup><xref rid="r3" ref-type="bibr">3</xref></sup> PLCA is a
skin-limited amyloidosis that does not involve internal organs. Histologically, it
is characterized by the deposition of amyloid in the superficial dermis. Clinically,
it is subclassified into 3 general categories: lichen (papular); macular (the most
common type); and nodular amyloid (the rarest).<sup><xref rid="r4" ref-type="bibr">4</xref></sup> Rare variants include the poikiloderma-like, bullous and
vitiliginous types, while anosacral forms have also been reported. However, the
classification involves considerable overlap, both within the subtypes of PLCA and
with systemic amyloidosis.<sup><xref rid="r5" ref-type="bibr">5</xref></sup> This
protean clinical manifestation also appears in patients with lichen lesions on the
face, external ear, neck and poikiloderma-like lesions on the upper back.</p>
      <p>Initial amyloid formation in PLCA is thought to be related to keratinocyte apoptosis.
But the general mechanism of amyloid fibril formation is not fully understood. Koji
Ono <italic>et al.</italic> proposed that the possible mechanism for promoting
amyloid fibril formation in PLCA may be summarized in 6 steps. Thus, galectin-7
(Gal-7) may be an amyloid precursor protein, while actin and cytokeratins may be
involved in modulating the aggregation of amyloidogenic peptides.<sup><xref rid="r6" ref-type="bibr">6</xref></sup></p>
      <p>Treating PLCA is difficult and numerous methods have been tried with variable
success. Systemic etretinate or acitretin appeared to be helpful in some cases, just
seen in this patient. The possible mechanisms were proposed as follows: First,
retinoids have anti-inflammatory and anti-proliferative actions that inhibit
epidermal acanthosis and further inflammatory injury to basal keratinocytes. They
are known to promote keratinocyte differentiation and can prevent amyloidogenesis by
correcting a keratin 5:14 imbalance. Second, they can regulate levels of several
heat-shock proteins that may prevent aberrant folding of keratin into amyloids.
Third, retinoids can also reduce apolipoprotein E secretion, a protein found
together with amyloids that is considered crucial in promoting its
formation.<sup><xref rid="r7" ref-type="bibr">7</xref></sup> As Gal-7 is an
important amyloid precursor protein in PLCA, further studies are necessary to
investigate the association between Gal-7 and retinoids.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="COI-statement">
        <p>Conflict of Interest: None</p>
      </fn>
      <fn fn-type="supported-by">
        <p>Financial Support: None</p>
      </fn>
      <fn fn-type="other" id="fn1">
        <label>*</label>
        <p>Work performed at the Third Affiliated Hospital, Sun Yat-sen University &#x2013;
Guangdong, China.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Norisugi</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Yamakoshi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shimizu</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Successful treatment of lichen amyloidosis using a CO2 surgical
laser</article-title>
          <source>Dermatol Ther</source>
          <year>2014</year>
          <volume>27</volume>
          <fpage>71</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="pmid">24703261</pub-id>
        </element-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dember</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>Amyloidosis-associated kidney disease</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2006</year>
          <volume>17</volume>
          <fpage>3458</fpage>
          <lpage>3471</lpage>
          <pub-id pub-id-type="pmid">17093068</pub-id>
        </element-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sipe</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Benson</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Buxbaum</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Ikeda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Merlini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Saraiva</surname>
              <given-names>MJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Amyloid fibril protein nomenclature: 2012 recommendations from
the Nomenclature Committee of the International Society of
Amyloidosis</article-title>
          <source>Amyloid</source>
          <year>2012</year>
          <volume>19</volume>
          <fpage>167</fpage>
          <lpage>170</lpage>
          <pub-id pub-id-type="pmid">23113696</pub-id>
        </element-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Brinster</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Calonje</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <chapter-title>The amyloidoses</chapter-title>
          <person-group person-group-type="author">
            <name>
              <surname>Calonje</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Brenn</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <source>McKee's Pathology of the Skin</source>
          <year>2011</year>
          <edition>4th ed</edition>
          <publisher-loc>Amsterdam</publisher-loc>
          <publisher-name>Elsevier Saunders</publisher-name>
          <fpage>532</fpage>
          <lpage>543</lpage>
        </element-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chandran</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Goh</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Goh</surname>
              <given-names>CL</given-names>
            </name>
          </person-group>
          <article-title>Case of primary localized cutaneous amyloidosis with protean
clinical manifestations: lichen, poikiloderma-like, dyschromic and bullous
variants</article-title>
          <source>J Dermatol</source>
          <year>2011</year>
          <volume>38</volume>
          <fpage>1066</fpage>
          <lpage>1071</lpage>
          <pub-id pub-id-type="pmid">21933256</pub-id>
        </element-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chandran</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Goh</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Goh</surname>
              <given-names>CL</given-names>
            </name>
          </person-group>
          <article-title>In vitro Amyloidogenic Peptides of Galectin-7: Possible Mechanism
of Amyloidogenesis of Primary Localized Cutaneous
Amyloidosis</article-title>
          <source>J Dermatol</source>
          <year>2011</year>
          <volume>38</volume>
          <fpage>1066</fpage>
          <lpage>1071</lpage>
          <pub-id pub-id-type="pmid">21933256</pub-id>
        </element-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Choi</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Sippe</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Acitretin for lichen amyloidosus</article-title>
          <source>Australas J Dermatol</source>
          <year>2008</year>
          <volume>49</volume>
          <fpage>109</fpage>
          <lpage>113</lpage>
          <pub-id pub-id-type="pmid">18412814</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
